A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia

Plk inhibitor, Phase I/II trial, acute myeloid leukaemia, non-intensive

Saved in:

Bibliographic Details
Main Authors:	Müller-Tidow, Carsten (Author) , Bug, Gesine (Author) , Lübbert, Michael (Author) , Krämer, Alwin (Author) , Krauter, Jürgen (Author) , Valent, Peter (Author) , Nachbaur, David (Author) , Berdel, Wolfgang E. (Author) , Ottmann, Oliver G. (Author) , Fritsch, Holger (Author) , Munzert, Gerd (Author) , Garin-Chesa, Pilar (Author) , Fleischer, Frank (Author) , Taube, Tillmann (Author) , Döhner, Hartmut (Author)
Format:	Article (Journal)
Language:	English
Published:	16 August 2013
In:	British journal of haematology Year: 2013, Volume: 163, Issue: 2, Pages: 214-222
ISSN:	1365-2141
DOI:	10.1111/bjh.12518
Online Access:	Resolving-System, Volltext: http://doi.org/10.1111/bjh.12518 Verlag, Volltext: http://onlinelibrary.wiley.com/doi/10.1111/bjh.12518/full
Author Notes:	Carsten Müller-Tidow, Gesine Bug, Michael Lübbert, Alwin Krämer, Jürgen Krauter, Peter Valent, David Nachbaur, Wolfgang E. Berdel, Oliver G. Ottmann, Holger Fritsch, Gerd Munzert, Pilar Garin-Chesa, Frank Fleischer, Tillmann Taube, Hartmut Döhner

Description
Summary:	Plk inhibitor, Phase I/II trial, acute myeloid leukaemia, non-intensive
Physical Description:	Online Resource
ISSN:	1365-2141
DOI:	10.1111/bjh.12518